Cytosorbents Corporation
CTSO
$0.78
$0.034.40%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -262.78% | 231.72% | 81.25% | -184.82% | 35.56% |
| Total Depreciation and Amortization | -8.93% | 8.80% | -4.91% | -0.79% | -3.98% |
| Total Amortization of Deferred Charges | -0.31% | 0.11% | 0.00% | 0.21% | 1,875.70% |
| Total Other Non-Cash Items | 113.77% | -143.67% | -134.04% | 498.30% | -188.40% |
| Change in Net Operating Assets | -158.39% | 423.97% | 74.45% | -216.47% | 147.16% |
| Cash from Operations | -70.66% | 56.42% | -47.94% | 4.90% | 48.63% |
| Capital Expenditure | 53.93% | -1,657.14% | 96.97% | 54.47% | -753.93% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 175.87% | -110.42% | 18.00% | 62.59% | -45.26% |
| Cash from Investing | 141.73% | -179.24% | 62.00% | 58.46% | -151.26% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -- | -- | -- | -- | 100.00% |
| Issuance of Common Stock | -- | -- | 3,993.53% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -20,400.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 100.00% | 92.66% |
| Cash from Financing | 100.00% | -100.02% | 3,993.53% | 268.59% | -101.01% |
| Foreign Exchange rate Adjustments | -156.35% | 900.39% | 124.46% | -224.59% | 221.78% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -92.80% | -141.36% | 239.10% | 13.35% | -157.22% |